Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Q1 2022 Earnings Presentation
22 slides from Observe Medical ASA's earnings presentation, Jun 3, 2022
Slide 1: Business update | Financial report Q1 2022
OBSERVE MEDICAL Business update | Financial report Q1 2022 3 June 2022
Slide 2: Presenting team
INTRODUCTION Presenting team Rune Nystad Per Arne Nygård Chief Executive Officer Chief Financial Officer Observe Medical Observe Medical 20+ years of experience from global 20+ years of experience from finance medtech and industrial technology from and accounting in various sectors the Nordics, US,
Slide 3: Nordic medtech company with global reach
WHO WE ARE | WHAT WE DO Nordic medtech company with global reach Commercializing proprietary innovative medtech products on a global market International distributor and partner network and Nordic direct sales operations Solid platform for further organic growth and through targeted M&A Patient welf
Slide 4: Progress and Q1 highlights
UPDATE Progress and Q1 highlights Operational status Q1 financial highlights • Preparing and strengthening the platform for growth • Revenues NOK 7.7 million • Streamlining organization and other operational synergies • Gross margin 43.7% following acquisition of Biim Ultrasound • Biim Ultrasound in
Slide 5: Status: Biim
RECENT EVENTS AND THE ROAD AHEAD Status: Biim • Continuing Biim roll-out with Fresenius Kidney Care educational centres throughout the USA • Strong engagement with Fresenius c-level team to ensure success • Need drives distribution to clinics in Costa Rica and Hawaii • Training of key personnel acro
Slide 6: Status: Sippi®
RECENT EVENTS AND THE ROAD AHEAD Status: Sippi® • Alignment of commercial strategies, country specific • Prepared a regulatory pathway in the US • Successful medical device regulation (MDR) process in Europe • Production partner closes down manufacturing in Belarus • Working with potential manufactu
Slide 7: Status: Nordic sales and distribution
RECENT EVENTS AND THE ROAD AHEAD Status: Nordic sales and distribution Medtech portfolio of devices and disposables • Covid situation improves for hospitals visits Sales performance • New contract secured for anaesthesia tubes in Uppsala, Mora, Ørebro NOK 3.6 mill +14% Q1 2022 compared to • New cont
Slide 8: Q1 2022 financials
Q1 2022 financials 9
Slide 9: Financial Highlights
FINANCIALS Q1 2022 Financial Highlights Revenue and gross results Q1 2022** Sales performance in the first quarter 24,042 • Revenue growth +148% Y-O-Y*, driven by strong sales for the Nordic distribution portfolio in Q1 and for the Biim Gross 9,519 ultrasound probe in March 2022 margin 9,519 39.6% •
Slide 10: Key figures: Profit and loss statement
FINANCIAL REVIEW Key figures Profit and loss statement Amounts in NOK thousand Q1 2022 Q1 2021 FY 2021 Q1 2022 • +14% revenue growth Y-O-Y from Operating revenues 7 713 3 110 24 042 Nordic portfolio and approximately NOK 4 million in revenues from Biim Gross result 3 367 844 9 519 ultrasound probe.
Slide 11: Key figures: Statement of financial position
FINANCIAL REVIEW Key figures Statement of financial position (Amounts in NOK thousand) At 31 March 2022 At 31 March 2021 At 31 December 2021 • Non-current assets consist of: ASSETS – Goodwill, – intangible assets related to Non-current assets Sippi® and Biim probe, Goodwill 82 134 33 933 33 870 – Ta
Slide 12: Key figures: Statement of financial position
FINANCIAL REVIEW Key figures Statement of financial position (Amounts in NOK thousand) At 31 March 2022 At 31 March 2021 At 31 December 2021 EQUITY AND LIABILITIES • Equity of TNOK 177,938 at 31 March 2022. Total equity 177 938 6 632 -14 122 • Non-current interest-bearing Non-current liabilities lia
Slide 13: Key figures: Cash flow statement Q1 2022
FINANCIAL REVIEW Key figures Cash flow statement Q1 2022 (Amounts in NOK thousand) • Cash flow used in operating 80 000 activities mainly related to the 131,029 70,992 EBIT result Q1 2022 affected by 70 000 -2,465 increased headcount and the 60 000 Biim acquisition 50 000 40 000 • Cash flow used in
Slide 14: Nordic medtech company with global reach
Nordic medtech company with global reach 15
Slide 15: Q1 2022 financials – Appendix
Q1 2022 financials Appendix 16
Slide 16: Profit and loss statement
UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2022 Profit and loss statement (Amounts in NOK thousand) Q1 2022 Q1 2021 FY 2021 Operating revenues 7 713 3 110 24 042 Cost of materials 4 345 2 265 14 524 Gross result 3 367 844 9 519 Employee benefit expenses 5 825 4 124 19 013 Other operating expenses 5 547
Slide 17: Statement of financial position
UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2022 Statement of financial position (Amounts in NOK thousand) At 31 March 2022 At 31 March 2021 At 31 December 2021 ASSETS Non-current assets Goodwill 82 134 33 933 33 870 Intangible assets 101 381 19 521 21 328 Tangible assets 3 911 1 189 1 381 Total non-cur
Slide 18: Statement of financial position
UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2022 Statement of financial position (Amounts in NOK thousand) At 31 March 2022 At 31 March 2021 At 31 December 2021 EQUITY AND LIABILITIES Total equity 177 938 6 632 -14 122 Non-current liabilities Non-current lease liabilities 1 683 610 550 Contingent consid
Slide 19: Cash flow statement
UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2022 Cash flow statement (Amounts in NOK thousand) Q1 2022 Q1 2021 FY 2021 Cash flow from operating activities Result before tax -9 007 -4 819 -26 321 Tax paid 86 0 -192 Depreciation and impairment 1 713 798 3 463 Gain(-)/ loss from sale of fixed asset 0 0 -6
Slide 20: Top shareholders
AS OF 31 MAY 2022 Top 20 shareholders Rank Name Number of shares % of top 20 % of total Country 1 INGERØ REITEN INVESTMENT COMPANY AS 9 653 680 25.76 % 18.05 % Norway 2 NAVAMEDIC ASA 4 222 727 11.27 % 7.89 % Norway 3 JPB AS 2 830 209 7.55 % 5.29 % Norway 4 RO, LARS 2 670 762 7.13 % 4.99 % Norway 5 E
Slide 21: Definitions of Alternative Performance Measures (APM)
OBSERVE MEDICAL Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result EBITDA
Slide 22: Observe Medical
oReonserve medical